Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 77 citing articles:

Therapeutic advances in rheumatoid arthritis
Philip M. Brown, Arthur G. Pratt, Kimme L Hyrich
BMJ (2024), pp. e070856-e070856
Open Access | Times Cited: 71
Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story
Michael Bonelli, Andreas Kerschbaumer, Kastriot Kastrati, et al.
Annals of the Rheumatic Diseases (2023) Vol. 83, Iss. 2, pp. 139-160
Open Access | Times Cited: 45
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician
Zoltán Szekanecz, Maya H Buch, Christina Charles‐Schoeman, et al.
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 2, pp. 101-115
Closed Access | Times Cited: 45
Cardiovascular safety of Janus kinase inhibitors in inflammatory bowel disease: a systematic review and network meta-analysis
Huibin Yang, Ting An, Yuxuan Zhao, et al.
Annals of Medicine (2025) Vol. 57, Iss. 1
Open Access | Times Cited: 2
Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme
Roy Fleischmann, Jeffrey R. Curtis, Christina Charles‐Schoeman, et al.
Annals of the Rheumatic Diseases (2023), pp. ard-223916
Open Access | Times Cited: 30
Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors
Lise T. Jensen, Kathrine E. Attfield, Marc Feldmann, et al.
EBioMedicine (2023) Vol. 97, pp. 104840-104840
Open Access | Times Cited: 28
Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors
Victor Yang, Tue Wenzel Kragstrup, Christopher McMaster, et al.
Drug Safety (2023) Vol. 46, Iss. 11, pp. 1049-1071
Open Access | Times Cited: 27
Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs
Lina Alhanshali, Michael G Buontempo, Kristen I. Lo Sicco, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 803-820
Open Access | Times Cited: 25
Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
Peter C. Taylor, Thomas Bieber, Rieke Alten, et al.
Advances in Therapy (2023) Vol. 40, Iss. 4, pp. 1867-1883
Open Access | Times Cited: 24
Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register
Yvette Meißner, Martin Schäfer, Katinka Albrecht, et al.
RMD Open (2023) Vol. 9, Iss. 4, pp. e003489-e003489
Open Access | Times Cited: 22
JAK inhibitor selectivity: new opportunities, better drugs?
Anniina Virtanen, Francesca Romana Spinelli, Jean Baptiste Telliez, et al.
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 10, pp. 649-665
Closed Access | Times Cited: 12
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester, Jacques‐Eric Gottenberg, Roberto Caporali, et al.
Annals of the Rheumatic Diseases (2024), pp. ard-225759
Open Access | Times Cited: 7
A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience
Peter C. Taylor, Cédric J. Laedermann, Rieke Alten, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 13, pp. 4527-4527
Open Access | Times Cited: 20
Safety of the JAK and TNF inhibitors in rheumatoid arthritis: real world data from the Hong Kong Biologics Registry
Chi Chiu Mok, Ho So, Cheuk Wan Yim, et al.
Lara D. Veeken (2023) Vol. 63, Iss. 2, pp. 358-365
Closed Access | Times Cited: 17
Recommendations for assessing the risk of cardiovascular disease and venous thromboembolism before the initiation of targeted therapies for chronic inflammatory rheumatic diseases
Jérôme Avouac, O. Fogel, Sophie Hecquet, et al.
Joint Bone Spine (2023) Vol. 90, Iss. 5, pp. 105592-105592
Open Access | Times Cited: 16
Cardiovascular events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately to severely active ulcerative colitis
Séverine Vermeire, David T. Rubin, Laurent Peyrin-Biroulet, et al.
BMJ Open Gastroenterology (2025) Vol. 12, Iss. 1, pp. e001516-e001516
Open Access
Cardiovascular, cancer, and infection risks of Janus kinase inhibitors in rheumatoid arthritis and ulcerative colitis: A nationwide cohort study
Yongtai Cho, Dongwon Yoon, Farzin Khosrow‐Khavar, et al.
Journal of Internal Medicine (2025)
Open Access
Do newly approved drugs have a worse observed safety profile than once established? A study on time trends in risks of key safety outcomes with immunomodulatory drugs against rheumatoid arthritis
Viktor Molander, Hannah Bower, Thomas Frisell, et al.
Annals of the Rheumatic Diseases (2025)
Open Access
Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update
Peter Nash, Andreas Kerschbaumer, Victoria Konzett, et al.
Annals of the Rheumatic Diseases (2025)
Open Access
Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes
Xavier Mariette, Sven Borchmann, Sandrine Aspeslagh, et al.
RMD Open (2025) Vol. 11, Iss. 1, pp. e005033-e005033
Open Access
Recombinant Zoster Vaccine Reduces All‐Cause Mortality, But Not Major Adverse Cardiovascular Events, in Patients With Immune‐Mediated Inflammatory Diseases Receiving Janus Kinase Inhibitors: A Large‐Scale Real‐World Retrospective Cohort Study
Po‐Cheng Shih, Shiow‐Ing Wang, Pui‐Ying Leong, et al.
Journal of Medical Virology (2025) Vol. 97, Iss. 3
Closed Access
JAK Inhibitors and B Cell Function: A Comparative Study of Their Impact on Plasma Cell Differentiation, Cytokine Production, and Naïve B Cell Activation
Wenqi Huang, Charlotte de Vries, Ravi Sharma, et al.
European Journal of Immunology (2025) Vol. 55, Iss. 3
Open Access
MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
Christina Charles‐Schoeman, Ernest Choy, Iain B. McInnes, et al.
RMD Open (2023) Vol. 9, Iss. 4, pp. e003392-e003392
Open Access | Times Cited: 15
Risk of venous thromboembolism with janus kinase inhibitors in inflammatory immune diseases: a systematic review and meta-analysis
J Zhang, Wenhui Li, Mingli Gong, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 14
Development and validation of a multiplex HPLC-MS/MS assay for the monitoring of JAK inhibitors in patient plasma
Jérémie Tachet, François Versace, Thomas Mercier, et al.
Journal of Chromatography B (2023) Vol. 1230, pp. 123917-123917
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top